Approximately 28 million Americans have been diagnosed with heart disease.1 Traditional therapies, however, do not fully address every aspect of heart damage, and transplant organs are difficult to obtain. Human induced pluripotent stem cell-derived cardiomyocytes(iPSC-CMs) have immense potential for human disease modeling. When cultured, researchers can use patient derived iPSC-CMs to study drug efficacy and disease mechanisms. However, iPSCs begin with an embryonic phenotype, and researchers have yet to advance iPSC-CMs to a mature stage where they simulate functional heart tissue. Although scientists continue to experiment with various culture protocols, current methods are costly and time consuming.
The most exciting thing was not only seeing [the results], but then seeing other benefits that had nothing to do with what we were targeting.
- Stuart Campbell, Yale University
In a recent study published in Stem Cell Reports, Stuart Campbell and his team at Yale University presented a novel culturing method that accelerates ...
